WuXi Diagnostics Secures US$150 Million Series B Financing to Accelerate Market Penetration in Global Diagnostics Sector

– WuXi Diagnostics secured a US$150m Series B financing round to accelerate market penetration in the global diagnostics sector.
– The round was joined by new investors including Thermo Fisher, Shiyu Capital, ABC International, Sunland Capital, and CCBI Tech Venture.
– WuXi Diagnostics will deploy funds to strengthen its open-access innovation enabling platform, advance its integrated diagnostics R&D pipeline, and accelerate market penetration in the global diagnostics sector.
– WuXi Diagnostics is the first platform company in China focusing on integrated diagnostics. Since its establishment in 2018, WuXi Diagnostics has continuously promoted the clinical practice of integrated diagnostics by virtue of its open-access innovation enabling platform, centered on multi-omics clinical data from multidisciplinary technologies.